Listed

Protalix BioTherapeutics, Inc.: Form 10-Q for the period ended Jun 30, 2020

Filed with the SEC on Aug 10, 2020 and accepted by EDGAR at Aug 10, 2020, 07:04 ET.

Share

Sections

The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2020-06-30. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Revenue3 months2020-04-01 to 2020-06-30$11.0mus-gaap:Revenues
Revenue6 months2020-01-01 to 2020-06-30$32.6mus-gaap:Revenues
Cost of revenue3 months2020-04-01 to 2020-06-30$1.8mus-gaap:CostOfRevenue
Cost of revenue6 months2020-01-01 to 2020-06-30$5.3mus-gaap:CostOfRevenue
Research and development3 months2020-04-01 to 2020-06-30$9.2mus-gaap:ResearchAndDevelopmentExpense
Research and development6 months2020-01-01 to 2020-06-30$19.5mus-gaap:ResearchAndDevelopmentExpense
Selling, general and administrative3 months2020-04-01 to 2020-06-30$2.2mus-gaap:SellingGeneralAndAdministrativeExpense
Selling, general and administrative6 months2020-01-01 to 2020-06-30$5.4mus-gaap:SellingGeneralAndAdministrativeExpense
Operating income3 months2020-04-01 to 2020-06-30−$2.2mus-gaap:OperatingIncomeLoss
Operating income6 months2020-01-01 to 2020-06-30$2.5mus-gaap:OperatingIncomeLoss
Net income3 months2020-04-01 to 2020-06-30−$4.2mus-gaap:NetIncomeLoss
Net income6 months2020-01-01 to 2020-06-30−$2.5mus-gaap:NetIncomeLoss
Diluted EPS3 months2020-04-01 to 2020-06-30−$0.13us-gaap:EarningsPerShareBasicAndDiluted
Diluted EPS6 months2020-01-01 to 2020-06-30−$0.12us-gaap:EarningsPerShareBasicAndDiluted
Operating cash flow6 months2020-01-01 to 2020-06-30−$15.0mus-gaap:NetCashProvidedByUsedInOperatingActivities
Capital expenditure6 months2020-01-01 to 2020-06-30$278.0kus-gaap:PaymentsToAcquirePropertyPlantAndEquipment
Cash and equivalentsAt period end2020-06-30$4.8mus-gaap:CashAndCashEquivalentsAtCarryingValue
Current assetsAt period end2020-06-30$54.2mus-gaap:AssetsCurrent
Total assetsAt period end2020-06-30$71.7mus-gaap:Assets
Current liabilitiesAt period end2020-06-30$42.4mus-gaap:LiabilitiesCurrent
Total liabilitiesAt period end2020-06-30$106.5mus-gaap:Liabilities
Shareholders' equityAt period end2020-06-30−$34.8mus-gaap:StockholdersEquity

Source: SEC EDGAR, the filing index for accession 0001104659-20-092375. Last ingested by Listed: Nov 10, 2026, 16:48 ET. Listed shows no prices and gives no investment advice.